Unlike other studies, our experimental approach allowed assessing a bone response to CKD before the development of hyperphosphatemia and systemic elevation of conventional phosphate regulatory factors, FGF23 and PTH [6,7,8,11,12,13,15,20,21,25]. The gene discussed is FGF23; the disease is chronic kidney disease.